Drug Profile
Research programme: antiparasitics - Helix BioMedix
Latest Information Update: 17 Oct 2008
Price :
$50
*
At a glance
- Originator Helix BioMedix
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Leishmaniasis
Most Recent Events
- 24 Jan 2007 Preclinical trials in Leishmaniasis in USA (unspecified route)